Appetite stimulants

Avicanna Completes First Commercial Export of Aureus™ Branded THC Active Pharmaceutical Ingredients to Peru

Retrieved on: 
Tuesday, August 3, 2021
Euphoriants, Entheogens, Medicinal plants, Psychoactive drugs, Drugs, Branches of biology, Appetite stimulants, Antiemetics, Tetrahydrocannabinol, Cannabis, Medical cannabis

TORONTO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that, through its majority-owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH”), it has completed its first commercial export into Peru of high concentration THC, full spectrum psychoactive cannabis crude oil, marketed under Avicanna’s Aureus™ brand, to Peru.

Key Points: 
  • Believed to be the first commercial export of psychoactive THC cannabis extract from Colombia to Peru.
  • (SMGH), it has completed its first commercial export into Peru of high concentration THC, full spectrum psychoactive cannabis crude oil, marketed under Avicannas Aureus brand, to Peru.
  • Lucas Nosiglia, President of Avicanna LATAM S.A.S., commented: We are pleased to enter the growing Peruvian market and integrate Peru into our rapidly advancing supply chain and commercial platform.
  • Additionally, under the Aureus brand, standardized cannabis extracts and feminized seeds are made available to cultivation, cosmetic and pharmaceutical partners around the world.

Eighty Six Brand: Delivering Convenience with the Delta-8 THC Disposables Collection

Retrieved on: 
Friday, July 30, 2021
Psychoactive drugs, Drugs, Branches of biology, Euphoriants, Appetite stimulants, Entheogens, Antiemetics, Medicinal plants, Delta-8-Tetrahydrocannabinol, Tetrahydrocannabinol, Cannabis, Medical cannabis

Eighty Six Brand takes the process one step further by adding a touch of convenience to the mix with its all-new Delta-8 THC Disposables collection.

Key Points: 
  • Eighty Six Brand takes the process one step further by adding a touch of convenience to the mix with its all-new Delta-8 THC Disposables collection.
  • The Eighty Six Brand Delta-8 Disposables collection features five of its most popular strains to date.
  • While certain states may have specific regulations and laws pertaining to the purchase and consumption of it, Delta-8 THC is federally legal.
  • If you live in a state where recreational cannabis is illegal, or simply looking for a way to experience a milder and more manageable psychoactive experience, Eighty Six Brand's all-new Delta-8 THC Disposables collection proves a viable alternative.

Next Frontier Brands' Subsidiary TreeHouse Biosciences™ Announces the Launch of its THC Remediation Services Business Based on Patented Technology

Retrieved on: 
Thursday, July 29, 2021
Euphoriants, Entheogens, Appetite stimulants, Drugs, Psychoactive drugs, Medical specialties, Herbs, Antiemetics, Hemp, Tetrahydrocannabinol, Cannabinoid, Cannabis

This method utilizes chromatography, a process which separates chemical compounds based on their unique molecular properties.

Key Points: 
  • This method utilizes chromatography, a process which separates chemical compounds based on their unique molecular properties.
  • TreeHouse Biosciences also has filed a patent for the removal of THC from hemp extracts utilizing a mild combination of heat and oxygen.
  • Treehouse Biosciencesnow provides THC remediation services through its Boulder, Colorado operations, and intends to build remote modular processing units in selected states where hemp processing is prominent.
  • Treehouse Biosciencesis a leader in the research, development and production of hemp-derived cannabinoid ingredients,and purification and remediation technologies.

Avicanna Completes First Commercial Export of Aureus™ Branded THC Extracts to Austria and Welcomes Colombian Government’s Progressive New Regulation on Cannabis

Retrieved on: 
Wednesday, July 28, 2021
Entheogens, Euphoriants, Medicinal plants, Psychoactive drugs, Branches of biology, Drugs, Appetite stimulants, Herbalism, Cannabis, Tetrahydrocannabinol, Medical cannabis, Hemp

TORONTO, July 28, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“SMGH”), it has completed its first commercial export of high concentration THC full spectrum psychoactive cannabis extracts to Austria. Additionally, the company welcomes the new Colombian regulation aimed at progressing the cannabis industry and its commercialization processes which positively impacts several of Avicanna’s business units and infrastructure in Colombia.

Key Points: 
  • This initial export to Austria marks Avicannas first commercial export of psychoactive THC Cannabis Extracts into the emerging European medicinal cannabis market.
  • (SMGH), it has completed its first commercial export of high concentration THC full spectrum psychoactive cannabis extracts to Austria.
  • Additionally, the company welcomes the new Colombian regulation aimed at progressing the cannabis industry and its commercialization processes which positively impacts several of Avicannas business units and infrastructure in Colombia.
  • This shipment marks the 9th country to which SMGH has exported the Aureus branded products, which include a range of CBD, THC and CBG extracts and feminised seeds.

Global Cannabidiol Market Size Expected to Reach $2.8 Billion by 2028 with a CAGR of 21%

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Organ systems, Psychoactive drugs, Cannabinoids, Resorcinols, Appetite stimulants, Entheogens, Euphoriants, Cannabidiol, Cannabis, Hemp

A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.

Key Points: 
  • A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.
  • Grand View added: "Furthermore, the use of hemp-derived CBD is increasing rapidly owing to its anti-inflammatory, anti-aging, and antioxidant properties.
  • This rapidly progressing transformation of cannabidiol from herbal preparations to prescription drugs is anticipated to boost the growth of the market.
  • Furthermore, growing awareness about the medical benefits of cannabidiol, including its healing properties, is anticipated to drive the product demand in the pharmaceutical industry."

NEOGEN Launches Reveal® Q+ for Δ9-THC in Hemp

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Psychoactive drugs, Euphoriants, Appetite stimulants, Entheogens, Organ systems, Cannabis, Cannabinoids, Tetrahydrocannabinol, Hemp, Cannabidiol

NEOGEN's new Reveal Q+ for 9-THC can precisely detect and report THC levels between 0.1% and 1.6%, providing fast, reliable, and on-demand crop monitoring.

Key Points: 
  • NEOGEN's new Reveal Q+ for 9-THC can precisely detect and report THC levels between 0.1% and 1.6%, providing fast, reliable, and on-demand crop monitoring.
  • "The addition of the ability to test for 9-THC to our Reveal Q+ portfolio puts the power in the hands of hemp farmers," says John Adent, NEOGEN's President and CEO.
  • Hemp has various uses, including rope and textiles, feed and grain, and cannabidiol (CDB), commonly used in body care products and supplements.
  • NEOGEN Corporation develops and markets comprehensive solutions dedicated to food and animal safety.

Global Cannabidiol Market Size Expected to Reach $2.8 Billion by 2028 with a CAGR of 21%

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Organ systems, Psychoactive drugs, Cannabinoids, Resorcinols, Appetite stimulants, Entheogens, Euphoriants, Cannabidiol, Cannabis, Hemp

PALM BEACH, Fla., July 28, 2021 /PRNewswire/ -- Cannabidiol derived from hemp is anticipated to witness rapid growth owing to increasing demand from the pharmaceutical sector and rising awareness among consumers regarding health. Increasing consumer disposable income along with the legalization of medicinal cannabis is anticipated to have a positive impact on the demand for cannabidiol in the pharmaceutical sector. Oils, tinctures, concentrate, capsules, topical solutions such as slaves, lip balms, lotions, and edibles such as baked goods, coffee, chocolates, gums, and candies are some of the CBD products which are in high demand. Due to its healing properties, the demand for cannabidiol (CBD) for health and wellness purposes is high, which is the major factor driving the market growth. In addition, the rising acceptance and use of products due to government approvals is a major factor expected to boost production for CBD-infused products.  A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.  Active Companies in the merchant industry include Grove, Inc. (NASDAQ: GRVI), Tilray, Inc. (NASDAQ: TLRY) (TSX: TLRY), Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), Pressure BioSciences, Inc. (OTCQB: PBIO), cbdMD, Inc. (NYSE: YCBD).

Key Points: 
  • A report from Grand View said that the global cannabidiol market size was valued at USD 2.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028.
  • Grand View added: "Furthermore, the use of hemp-derived CBD is increasing rapidly owing to its anti-inflammatory, anti-aging, and antioxidant properties.
  • This rapidly progressing transformation of cannabidiol from herbal preparations to prescription drugs is anticipated to boost the growth of the market.
  • Furthermore, growing awareness about the medical benefits of cannabidiol, including its healing properties, is anticipated to drive the product demand in the pharmaceutical industry."

Biomedican Receives Approval Notification From the U.S. Patent Office on Its 1st Patent

Retrieved on: 
Tuesday, July 27, 2021
Drugs, Euphoriants, Cannabinoid, Psychoactive drugs, Appetite stimulants, Entheogens, Yarrowia, Tetrahydrocannabinol, Patent, Branches of biology

SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Biomedican has received notification from the U.S. patent office that its first patent has been approved and will be issued in the coming months.

Key Points: 
  • SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Biomedican has received notification from the U.S. patent office that its first patent has been approved and will be issued in the coming months.
  • This is the first patent ever to be issued using Yarrowia Lipolytica to produce cannabinoids.
  • Enzymes which are converting CBGA into CBDA, CBCA and THCA are required for the presence of interaction of two phases: oil and water.
  • "Patenting the use of Yarrowia Lipolytica to produce cannabinoids gives Biomedican a significant competitive advantage in the biosynthesized cannabinoid market.

THC BioMed Announces Shipment to Yukon

Retrieved on: 
Friday, July 23, 2021
Psychoactive drugs, Entheogens, Euphoriants, Medicinal plants, Drugs, Branches of biology, Appetite stimulants, Herbalism, Cannabis, Tetrahydrocannabinol, Medical cannabis, Effects of cannabis

VANCOUVER, BC, July 23, 2021 /PRNewswire/ -THC BioMed Intl Ltd. ("THC BioMed" or the "Company" is pleased to announced that it has completed its first shipment to Yukon Cannabis.

Key Points: 
  • VANCOUVER, BC, July 23, 2021 /PRNewswire/ -THC BioMed Intl Ltd. ("THC BioMed" or the "Company" is pleased to announced that it has completed its first shipment to Yukon Cannabis.
  • The shipment contains dried cannabis and cannabis cookies.
  • THC BioMed is one of Canada's oldest active licensed cannabis companies.
  • THC BioMedis a Cannabis Act Licensed Producer of medical and recreational cannabis.

THC BioMed Announces Shipment to Yukon

Retrieved on: 
Friday, July 23, 2021
Psychoactive drugs, Entheogens, Euphoriants, Medicinal plants, Drugs, Branches of biology, Appetite stimulants, Herbalism, Cannabis, Tetrahydrocannabinol, Medical cannabis, Effects of cannabis

VANCOUVER, BC, July 23, 2021 /PRNewswire/ -- THC BioMed Intl Ltd. ("THC BioMed" or the "Company" is pleased to announced that it has completed its first shipment to Yukon Cannabis. The shipment contains dried cannabis and cannabis cookies.

Key Points: 
  • VANCOUVER, BC, July 23, 2021 /PRNewswire/ --THC BioMed Intl Ltd. ("THC BioMed" or the "Company" is pleased to announced that it has completed its first shipment to Yukon Cannabis.
  • The shipment contains dried cannabis and cannabis cookies.
  • THC BioMed is one of Canada's oldest active licensed cannabis companies.
  • THC BioMedis a Cannabis Act Licensed Producer of medical and recreational cannabis.